US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AMPLIFY SAMSUNG SOFR ETF

100.61

+0.0000

Volume:- -

Turnover:70.43K

Market Cap:170.02M

PE:- -

High:100.61

Open:100.61

Low:100.61

Close:100.61

Loading ...

Overview Company News Filings

Palladyne AI Selected for Participation at USSOCOM TE25-2: Collaborative Autonomy Integration Event

South Bow Reports Fourth-quarter and Year-end 2024 Results, Provides 2025 Outlook, and Declares Dividend

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

Viasat Secures $568M Defense Contract: Will This Benefit the Stock?

Palantir's Stock Surges Amid Strategic Moves and AI Advancements

U.S. Special Operations Command Expands Contract with Palantir to Deliver Advanced AI and Mission Manager Capabilities

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

L3Harris Electronic Warfare System Completes Safety of Flight Testing

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

Noxopharm Finalizes SOF-SKN Formula, Gains Global Interest

OSS Enters into a Cooperative Research and Development Agreement with the U.S. Special Operations Command

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/SOF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SOF"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SOF\",,,,,undefined,":{"symbol":"SOF","market":"US","secType":"STK","nameCN":"AMPLIFY SAMSUNG SOFR ETF","latestPrice":100.6065,"timestamp":1727294400000,"preClose":100.6065,"halted":8,"volume":0,"delay":0,"changeRate":0,"change":0,"floatShares":1690000,"shares":1690000,"lyrEps":0,"amount":70432.1191,"amplitude":0,"dividePrice":5.30327},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SOF\",,,,,undefined,":{"symbol":"SOF","floatShares":1690000,"roa":"--","roe":"--","lyrEps":0,"shares":1690000,"dividePrice":5.30327,"high":100.6065,"amplitude":0,"preClose":100.6065,"low":100.6065,"week52Low":100.04,"pbRate":"--","week52High":100.6948,"institutionHeld":0,"latestPrice":100.6065,"eps":0,"divideRate":0.052713,"volume":0,"delay":0,"ttmEps":0,"open":100.6065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SOF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-26","symbol":"SOF","oldSymbol":"SOF","defaultRemindTime":1727357400000,"newSymbol":"SOFR","exchange":"AMEX","type":"symbolChange","dateTimestamp":1727323200000},{"date":"2024-08-29","symbol":"SOF","amount":0.44758,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-29","defaultRemindTime":1724938200000,"name":"AMPLIFY SAMSUNG SOFR ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-30","payableDate":"2024-08-29","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-30"},{"date":"2024-07-30","symbol":"SOF","amount":0.44767,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-30","defaultRemindTime":1722346200000,"name":"AMPLIFY SAMSUNG SOFR ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-31","payableDate":"2024-07-30","currency":"USD","dateTimestamp":1722312000000,"payDate":"2024-07-31"},{"date":"2024-06-27","symbol":"SOF","amount":0.444978,"announcedDate":"2024-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"AMPLIFY SAMSUNG SOFR ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-06-28"},{"date":"2024-05-30","symbol":"SOF","amount":0.44516,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-05-30","defaultRemindTime":1717075800000,"name":"AMPLIFY SAMSUNG SOFR ETF","recordDate":"2024-05-31","payableDate":"2024-05-30","currency":"USD","dateTimestamp":1717041600000,"payDate":"2024-05-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SOF\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-26","recordDate":"2023-12-27","paymentDate":"2023-12-29","value":0.050309,"currency":"USD"},{"executeDate":"2024-01-29","recordDate":"2024-01-30","paymentDate":"2024-01-31","value":0.447536,"currency":"USD"},{"executeDate":"2024-02-27","recordDate":"2024-02-28","paymentDate":"2024-02-29","value":0.423232,"currency":"USD"},{"executeDate":"2024-03-26","recordDate":"2024-03-27","paymentDate":"2024-03-28","value":0.445772,"currency":"USD"},{"executeDate":"2024-04-26","recordDate":"2024-04-29","paymentDate":"2024-04-30","value":0.43153,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SOF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SOF\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518622261","title":"Palladyne AI Selected for Participation at USSOCOM TE25-2: Collaborative Autonomy Integration Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2518622261","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518622261?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:00","pubTimestamp":1741611600,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, March 10, 2025----Palladyne AI Corp.  , a developer of artificial intelligence software for robotic platforms in the defense and commercial sectors, today announced that the Company has been selected for participation at TE25-2: Collaborative Autonomy Integration, hosted by the U.S. Special Operations Command  Technical Experimentation Team and taking place from April 14-17, 2025, at Avon Park Air Force Range in Avon Park, FL. Palladyne AI will be showcasing its Palladyne Pilot AI Software Platform at the event.Palladyne AI software products operate on the edge and dramatically reduce the significant effort required to program and deploy robots enabling industrial robots and collaborative robots  to quickly achieve autonomous capabilities even in dynamic and or complex environments. Designed to achieve precise results with minimal t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palladyne-ai-selected-participation-ussocom-130000803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","AVP","PDYNW","BK4604","SOF","ML","PDYN","BK4161","BK4603"],"gpt_icon":0},{"id":"2517761729","title":"South Bow Reports Fourth-quarter and Year-end 2024 Results, Provides 2025 Outlook, and Declares Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2517761729","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517761729?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:12","pubTimestamp":1741219920,"startTime":"0","endTime":"0","summary":"CALGARY, Alberta, March  05, 2025  (GLOBE NEWSWIRE) -- South Bow Corp. (TSX & NYSE: SOBO) (South Bow or the Company) reports its fourth-quarter and year-end 2024 financial and operational results and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3037865/0/en/South-Bow-Reports-Fourth-quarter-and-Year-end-2024-Results-Provides-2025-Outlook-and-Declares-Dividend.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOF","SOBO","AIF","BK4144"],"gpt_icon":0},{"id":"2503303946","title":"Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2503303946","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503303946?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approxima","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008323/0/en/Atea-Pharmaceuticals-to-Highlight-2025-Strategic-Priorities-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1732799900.SGD","HCSG","LU0267386448.USD","IE00BKVL7J92.USD","BK4137","LU1548497426.USD","LU2271345857.HKD","BK4127","BK4585","LU0006306889.USD","BK4516","LU2347655156.SGD","LU1989772923.USD","LU1162221912.USD","LU1363072403.SGD","SOF","LU0158827781.USD","LU1074936037.SGD","LU0225283273.USD","LU0106261372.USD","LU0098860793.USD","BK4181","LU0106831901.USD","LU0158827948.USD","LU2028103732.USD","LU2089284900.SGD","LU1720051017.SGD","IE00BZ1G4Q59.USD","LU1720051108.HKD","BK4581","BK4534","LU1989772840.SGD","BK4588","LU1668664300.SGD","LU0795875086.SGD","LU0314104364.USD","LU0320765646.SGD","LU0912757837.SGD","LU0971096721.USD","PK","LU2023251221.USD","LU0795875169.SGD","LU1732800096.USD","LU2357305700.SGD","AVIR","BK4218","LU2089283258.USD","BK4504","LU2111349929.HKD"],"gpt_icon":0},{"id":"2490896724","title":"Viasat Secures $568M Defense Contract: Will This Benefit the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490896724","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490896724?lang=en_us&edition=fundamental","pubTime":"2024-12-12 01:05","pubTimestamp":1733936700,"startTime":"0","endTime":"0","summary":"Viasat brings an array of cutting-edge technologies and solutions, including tactical gateways, advanced networking systems, airborne satellite communication  terminals, ground terminals, modems, beyond-line-of-sight satellite services and robust cybersecurity and encryption capabilities. This contract will likely allow the U.S. Department of Defense to address key priorities such as enhancing mobility, ensuring resilient networking, improving cybersecurity, and expanding broadband SATCOM services.These advancements will enable SOF and GPF to deploy new operational capabilities, products and services, enhancing mission effectiveness and ensuring the safety of warfighters. Additionally, the contract will facilitate the rapid acquisition of emerging technologies, allowing military users across various services to maintain operational readiness through access to cutting-edge solutions.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XbuIpQrVk99nJInENBcC7Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/76b77267780db8a8e104d16effc1eb76","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XbuIpQrVk99nJInENBcC7Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/76b77267780db8a8e104d16effc1eb76"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viasat-secures-568m-defense-contract-170500702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4515","BK4023","BK4591","ERIC","IDCC","UI","SOF","VSAT","BK4020","BK4554"],"gpt_icon":1},{"id":"2490987705","title":"Palantir's Stock Surges Amid Strategic Moves and AI Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2490987705","media":"GuruFocus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490987705?lang=en_us&edition=fundamental","pubTime":"2024-12-09 23:55","pubTimestamp":1733759717,"startTime":"0","endTime":"0","summary":"Palantir Technologies (PLTR, Financial) has seen its shares nearly double in just over a month, driven by a series of positive announcements and market speculation. The company's Q3 earnings report sp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2627546/palantirs-stock-surges-amid-strategic-moves-and-ai-advancements","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4588","PLTR","BK4097","LU1861559042.SGD","BK4023","BK4585","AIP","LU1861558580.USD","SOF","BK4547","BK4543"],"gpt_icon":1},{"id":"2490726533","title":"U.S. Special Operations Command Expands Contract with Palantir to Deliver Advanced AI and Mission Manager Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2490726533","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490726533?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:59","pubTimestamp":1733745540,"startTime":"0","endTime":"0","summary":"DENVER, December 09, 2024----Palantir Technologies Inc.  today announced an expansion of its contract with the U.S. Special Operations Command  to deliver technology solutions in support of enterprise capabilities. The one-year delivery is valued at $36.8 million and establishes Palantir as the lead software integrator for USSOCOM’s Mission Command System  while expanding the technology solutions supporting U.S. Special Operations Forces  globally.This contract award leverages Palantir’s multi-vendor development ecosystem and the Ontology Software Development Kit  to expedite software deployment at the edge. The expanded partnership also enables pilot projects across the broader Command, inclusive of efforts dedicated to bringing Palantir’s cutting-edge artificial intelligence  capabilities to USSOCOM.This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0vPYHuikOikk.bfvSzDpuw--~B/aD01MjU7dz0yMTkxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1f9d6f0b00595e9fd65965b0fac418d0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0vPYHuikOikk.bfvSzDpuw--~B/aD01MjU7dz0yMTkxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1f9d6f0b00595e9fd65965b0fac418d0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-special-operations-command-expands-115900132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","BK4023","BK4108","BK4547","LU1861558580.USD","BK4157","SOF","IE00B7SZL793.SGD","AEIS","MCS","BK4585","BK4588","LU1861559042.SGD","IE00B19Z4B17.USD","PLTR","BK4543","IE0031619046.USD"],"gpt_icon":1},{"id":"2488516252","title":"Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488516252","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488516252?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:00","pubTimestamp":1733313600,"startTime":"0","endTime":"0","summary":"Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment  after Short Eight Week Treatment Duration. Global Phase 3 Program Initiation Expected Early in 2025. In the Phase 2 study, 99%  of treatment adherent patients who were non-cirrhotic and infected with genotypes 1-4 achieved SVR12, demonstrating robust pan-genotypic potency and supporting an eight-week treatment in the Phase 3 program. Treatment adherent patients with cirrhosis achieved a 88%  SVR12 rate. Viral kinetics were slower in these cirrhotic patients, however, all patients achieved 100% end of treatment response. To maximize efficacy, treatment duration in patients with cirrhosis will be 12 weeks in the Phase 3 program. Based on the high proportion of people between 20-49 years old who ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-announces-positive-results-120000112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","AVIR","BK4218","SOF","BK4181","PK"],"gpt_icon":0},{"id":"2483130645","title":"Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483130645","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483130645?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":"BOSTON, Nov. 15, 2024  -- Atea Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus . The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases’  The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.A multiscale HCV viral kinetic model was utilized to estimate the clinical effectiveness of the combination of bemnifosbuvir and ruzasvir in blocking HCV replication and viral assembly/secretion against HCV. This model evaluated the combination of bemnifosbuvir and ruzasvir in the lead-in cohort  of a Phase 2 single-ar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-presents-multiple-datasets-160000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1878469433.USD","QD","BK4218","BK4166","PK","SOF","AVIR","ALT","BK4181","BK4563","BK4503","BK4139","BK4007"],"gpt_icon":0},{"id":"2481458184","title":"L3Harris Electronic Warfare System Completes Safety of Flight Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2481458184","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481458184?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:00","pubTimestamp":1730991600,"startTime":"0","endTime":"0","summary":"MELBOURNE, Fla., November 07, 2024----L3Harris Technologies  has completed Safety of Flight  qualification on its Viper Shield all-digital electronic warfare  suite for F-16 fighter jets. The company will provide the advanced capability to F-16 fleets for six international partners.\"Completing the comprehensive SOF evaluation is a significant milestone for Viper Shield and for our growing list of global customers,\" said Ed Zoiss, President, Space and Airborne Systems, L3Harris. \"This critical electronic warfare system will begin flight testing soon, and we will start delivering the capability in late 2025.\". Viper Shield equips aircrews and commanders with situational awareness about the electronic landscape and helps them identify, locate and counter threats to enable survivability and lethality in the most challenging environments. It is the only advanced EW solution that is funded and in active production for international F-16 partners. By design, L3Harris engineered Viper Shield t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0YIHHrss_Wvlkcs.XOfnTw--~B/aD0yOTg7dz04NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a16424bf08ac3f5304073fabdf62c63","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0YIHHrss_Wvlkcs.XOfnTw--~B/aD0yOTg7dz04NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1a16424bf08ac3f5304073fabdf62c63"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/l3harris-electronic-warfare-system-completes-150000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","SOF","IE00BFXG1179.USD","LHX","EW","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4585","BK4187","BK4567","BK4588","BK4082"],"gpt_icon":0},{"id":"2479270562","title":"Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479270562","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479270562?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:00","pubTimestamp":1730286000,"startTime":"0","endTime":"0","summary":"BOSTON, Oct. 30, 2024  -- Atea Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus . The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases’  The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.“We look forward to presenting these important data, which support the combination of bemnifosbuvir and ruzasvir and its potential best-in-class profile for the treatment of HCV,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “The unrelenting high incidence rate of HCV infections ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R_jy000qdGewQIJiD_sBaA--~B/aD01MTM7dz05MDQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8af90bcf7484416abf6a1ff458b8f218"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-present-data-supporting-110000719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4218","PK","SOF","AVIR"],"gpt_icon":0},{"id":"2468872812","title":"Noxopharm Finalizes SOF-SKN Formula, Gains Global Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2468872812","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468872812?lang=en_us&edition=fundamental","pubTime":"2024-09-17 07:28","pubTimestamp":1726529311,"startTime":"0","endTime":"0","summary":"Noxopharm Ltd. (AU:NOX) has released an update. Noxopharm Limited has announced the completion of its SOF-SKN™ lupus medication formulation, a vita...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/noxopharm-finalizes-sof-skn-formula-gains-global-interest?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/noxopharm-finalizes-sof-skn-formula-gains-global-interest?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOF"],"gpt_icon":0},{"id":"2466279233","title":"OSS Enters into a Cooperative Research and Development Agreement with the U.S. Special Operations Command","url":"https://stock-news.laohu8.com/highlight/detail?id=2466279233","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466279233?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:00","pubTimestamp":1726142400,"startTime":"0","endTime":"0","summary":"Partnership to enhance cognitive dominance in support of Hyper Enabled Force mission objectives through development efforts of rugged edge AI/ML compute solutions Agreement aligns with OSS’ strategy t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/12/2945155/0/en/OSS-Enters-into-a-Cooperative-Research-and-Development-Agreement-with-the-U-S-Special-Operations-Command.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSS","SOF","ML","BK4166","BK4170"],"gpt_icon":0}],"pageSize":16,"totalPage":1,"pageCount":1,"totalSize":12}]}}